Federica Fabro joined Pepscope to pursue part of her Ph.D. research within the GLIOTRAIN consortium. She previously contributed to the development of vascularized 3D glioma models at Mimetas and she will now investigate mechanisms of drug resistance in glioblastoma multiforme by applying QuantaKinome™ as state-of-art technology to profile kinase activities in 2D and 3D glioma models.
GLIOTRAIN has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 766069.